AKTS AKTIS ONCOLOGY INC revenue, earnings and financials
For the quarter ended June 30, 2026, AKTIS ONCOLOGY INC reported revenue of $3.38M (up 111.4% from a year earlier), net income of −$24.1M and diluted EPS of −$0.44.
AKTS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.38M (up 111.4% year over year), net income −$24.1M, EPS −$0.44
- Quarter ended Mar 31, 2026: revenue $3.23M (up 123.0% year over year), net income −$18.3M, EPS −$0.38
- Quarter ended Jun 30, 2025: revenue $1.60M, net income −$18.1M, EPS −$22.39
- Quarter ended Mar 31, 2025: revenue $1.45M, net income −$15.0M, EPS −$18.60
AKTS balance sheet
- Jun 30, 2026: cash $82.5M, total assets $558M, total liabilities $72.8M, shareholders' equity $485M
- Mar 31, 2026: cash $372M, total assets $577M, total liabilities $70.7M, shareholders' equity $506M
- Dec 31, 2025: cash $37.8M, total assets $265M, total liabilities $77.6M, shareholders' equity −$146M